AI Lung Cancer Screening Software Approved in Europe, Boosting Digital Health Growth

The European digital health market is projected to expand at a 6% compound annual growth rate from 2025 to 2035, representing about 7% of the global market in 2025. In this context, Median Technologies announced that its AI‑powered lung‑cancer screening software, eyonis LCS, received a CE marking as a Class IIb Software as a Medical Device under the European Medical Device Regulation. The approval follows the product’s earlier clearance by the U.S. Food and Drug Administration in 2026 and enables commercialisation across the European Economic Area.

Eyonis LCS is designed to aid radiologists by automatically analysing low‑dose CT scans, detecting pulmonary nodules and estimating their probability of malignancy with AI‑driven computer‑aided diagnosis. Analysts note that such AI tools enhance imaging efficiency, improve diagnostic confidence and streamline reporting, while final clinical decisions remain with healthcare professionals. The regulatory endorsement is expected to further drive adoption of AI‑enabled digital‑health solutions throughout Europe.